# Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects

> **NCT06036784** · PHASE1 · COMPLETED · sponsor: **MBX Biosciences** · enrollment: 69 (actual)

## Conditions studied

- Postbariatric Hypoglycemia

## Interventions

- **DRUG:** MBX 1416 (Part A)
- **DRUG:** MBX 1416 (Part B)
- **DRUG:** Placebo
- **DRUG:** MBX 1416 (Part C)

## Key facts

- **NCT ID:** NCT06036784
- **Lead sponsor:** MBX Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-18
- **Primary completion:** 2024-11-14
- **Final completion:** 2024-12-05
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2024-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06036784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06036784, "Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06036784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*